SCHEMBL7142074

SCHEMBL7142074

Fc1ccc(-c2nc(-c3ccc(Cl)cc3)c[nH]2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 3/20 0.46
GCGR P47871 3/20 0.46
MAPK12 P53778 3/20 0.46
MAPK11 Q15759 3/20 0.46
MAPK14 Q16539 3/20 0.46
TP53 P04637 4/20 0.43
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
PSD A5PKW4 2/20 0.39
ALPL P05186 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7142932 0.98 MAPK13 (0.44) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL7137198 0.91 KDM4E (0.46) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL15029205 0.91 MAPK1 (0.42) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL26110507 0.84 KDM4E (0.45) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL3140919 0.84 NR1H2 (0.51) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL3136907 0.84 NR1H2 (0.51) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL7141855 0.84 KDM4E (0.45) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL26464181 0.83 MAPT (0.50) MAPTSMN1; SMN2TSHRHSD17B10KDM4E
SCHEMBL8311417 0.83 GCGR (0.51) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL3463135 0.81 MAPK1 (0.36) MAPK13GCGRMAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 CN disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed